AlixaRx Revenue and Competitors

Dallas, TX USA

Location

$100M

Total Funding

Estimated Revenue & Valuation

  • AlixaRx's estimated annual revenue is currently $37.2M per year.(i)
  • AlixaRx's estimated revenue per employee is $150,500
  • AlixaRx's total funding is $100M.

Employee Data

  • AlixaRx has 247 Employees.(i)
  • AlixaRx grew their employee count by 0% last year.

AlixaRx's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP Human ResourcesReveal Email/Phone
3
VPReveal Email/Phone
4
Financial Systems DirectorReveal Email/Phone
5
Business Development DirectorReveal Email/Phone
6
Regional Sales DirectorReveal Email/Phone
7
Pharmacy ManagerReveal Email/Phone
8
HR ManagerReveal Email/Phone
9
Operations Manager IIReveal Email/Phone
10
Finance ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.4M11-31%$11.4MN/A
#2
$0.5M16-24%$10.2MN/A
#3
$1.2M14-7%N/AN/A
#4
$15.7M112N/AN/AN/A
#5
$0.1M60%$4.7MN/A
#6
$15M1072%$23.1MN/A
#7
$0.9M11-8%N/AN/A
#8
$1M12-14%N/AN/A
#9
$174M8884%N/AN/A
#10
$25.7M167-5%N/AN/A
Add Company

What Is AlixaRx?

Our new pharmacy and clinical pharmacist services company was created with the direct input of patients, nurses, therapists, physicians and pharmacists. It was a collaboration of innovative thinking focused on improving access, increasing safety and maximizing time and cost savings.

keywords:Biotechnology

$100M

Total Funding

247

Number of Employees

$37.2M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

AlixaRx News

2013-07-02 - AlixaRx Receives $100M in Capital from Fillmore Capital Partners

AlixaRx, a Dallas-based provider of advanced pharmacy services in post-acute health care facilities, received $100m in capital from Fillmore Capital Partners. A spin-off of Drumm Corp., the company leverages technology to deliver medication therapy management. AlixaRx operates full-service phar ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$57.3M2486%N/A
#2
$43.8M24932%N/A
#3
$85M2516%N/A
#4
$40.6M2526%$73M
#5
$40.5M25433%N/A